section 01 — entity map
the web
Pharmaceutical companies, trade associations, former regulators, current officials, and political actors form an interlocking network in which money, personnel, and authority flow in all directions. The FDA sits at the center — funded by industry, staffed by industry alumni, and in 2025, targeted for dismantling by a political actor whose own company it regulates.
Trade associations / Lobby
Flagged — direct conflict
section 02 — the structural conflict
the agency that industry funds
Since 1992, pharmaceutical companies have paid the FDA to review their drug applications — a system called the Prescription Drug User Fee Act (PDUFA). The program was designed to speed up slow FDA reviews. It also created a structural conflict: the FDA depends on fees from the companies whose drugs it evaluates. In FY2024, pharma paid the FDA approximately $1.42 billion in user fees — roughly 45% of the FDA's total drug program budget.
What PDUFA Requires Companies to Pay
Under PDUFA VII (2023–2027), each new drug application (NDA) requiring clinical data costs $4,048,695 — payable to the FDA at submission. Companies with approved products pay an annual program fee of $416,734 per approved drug. In FY2024, these fees generated $284M in application revenue and $1.14B in program fees — a total of approximately $1.42B, covering ~45% of the FDA's human drug review budget.
Why This Creates a Conflict
The FDA sets internal performance goals — called PDUFA goals — based on the fees collected. Meeting these timelines (10 months for standard, 6 months for priority) is tied to continued fee appropriations. Critics including former FDA officials have noted that fee dependence creates institutional pressure to approve rather than reject: rejections slow the fee pipeline. A 2022 study in JAMA found that drugs approved in FDA's final review month (before PDUFA deadline) had more safety withdrawals than those approved earlier.
Primary source — Federal Register, FY2024 PDUFA Fee Schedule (2023-15911)
"The fee revenue amount to be derived from application fees in FY 2024 is $284,420,800 ... prescription drug program fee rates will be set to generate 80 percent of the total target revenue amounting to $1,137,683,200 in FY 2024."
| PDUFA Fee Type |
FY2024 Rate |
FY2025 Rate |
Change |
Note |
| NDA / BLA with clinical data |
$4,048,695 |
$4,171,237 |
+3% |
Paid at submission — before approval decision |
| NDA / BLA without clinical data |
$2,024,348 |
$2,085,619 |
+3% |
Lower tier — e.g., generic submissions |
| Annual program fee (per approved drug) |
$416,734 |
$429,036 |
+3% |
Recurring; estimated 2,730 paying products in FY2024 |
| Total PDUFA revenue target |
~$1.42B |
~$1.46B |
+3% |
~45% of FDA human drug program budget |
The documented paradox: The FDA cannot function — cannot pay its drug reviewers — without the fees generated by drug approvals. Its budget is structurally tied to the commercial success of the companies it regulates. PDUFA VII was reauthorized in 2022 after extensive negotiations between the FDA and the pharmaceutical industry — negotiations that critics note are conducted between a regulator and the regulated, with the public largely absent.
section 03 — the lobbying machine
$6.1 billion since 1999
The pharmaceutical and health products industry has been the single largest lobbying spender in the United States every year since 1999 — without exception. It has spent more than $6.1 billion on federal lobbying since that year. In 2024 alone, the industry spent $391.5 million — more than oil and gas, defense, technology, and finance. The primary targets: drug pricing legislation, FDA regulatory authority, and Medicare negotiation rules.
Pharmaceuticals/Health Products — annual federal lobbying spend (OpenSecrets LDA data)
$391.5M in 2024 · #1 every year since 1999
top spenders — 2024
| Entity |
2024 Lobbying (approx.) |
2023 |
2022 |
Primary Issue |
| PhRMA (trade association) |
$31M |
$27.6M |
$29.2M |
Drug pricing, Medicare negotiation, FDA authority |
| Pfizer Inc. |
$11.6M |
~$10M |
$14.9M |
COVID vaccine policy, drug pricing |
| Biotechnology Innovation Organization (BIO) |
$9.5M |
— |
— |
Biotech regulatory framework, IP protection |
| Roche Holdings |
$8.6M |
— |
— |
Drug pricing, diagnostic regulation |
| Amgen Inc. |
$8M |
$14.3M |
— |
IRA drug pricing provisions, Medicare |
| Eli Lilly, Novartis, Johnson & Johnson |
Top 10 |
Top 10 |
Top 10 |
Drug pricing, IRA rollback attempts |
Key finding — PhRMA lobbyist background (OpenSecrets, 2023)
130 of 203 PhRMA registered lobbyists in 2023 — 64% — previously held federal government positions. The revolving door between the agencies that regulate pharmaceuticals and the trade association that represents them is not incidental. It is the mechanism.
what $6.1 billion bought — the legislative record
1992
PDUFA enacted — industry wins the right to fund its own regulator
Prescription Drug User Fee Act · First major pharma regulatory win
After years of industry lobbying over "slow" FDA reviews, Congress passes PDUFA, allowing pharmaceutical companies to pay user fees directly to the FDA in exchange for faster review timelines. Industry frames it as a win for patients. Critics note it makes the FDA financially dependent on the companies it regulates. PDUFA has been reauthorized six times since — each time after negotiations between FDA and the pharmaceutical industry.
1995
OxyContin approved — FDA reviewers help Purdue draft the approval document
Purdue Pharma · Opioid crisis origin point · No addiction studies required
FDA approves OxyContin without long-term addiction studies. Documents later obtained by the Department of Justice show that the two principal FDA reviewers met with Purdue representatives and allowed the company to help draft the FDA medical officer's review — the official document used to approve the drug. The label's misleading language ("believed to reduce abuse liability") was approved without clinical evidence. Both FDA reviewers subsequently took positions at Purdue Pharma. OxyContin sales grew from $48M in 1996 to $1.1B by 2000. More than 500,000 Americans have died from opioid overdoses since 1999.
2003
Medicare Part D passed — pharma blocks government price negotiation
$400B program created with explicit prohibition on price negotiation
The Medicare Prescription Drug Improvement and Modernization Act creates Medicare Part D, the prescription drug benefit. The legislation explicitly prohibits Medicare from negotiating drug prices — a provision that PhRMA had lobbied intensively to include. The industry spent approximately $116M on lobbying in 2003, a record at the time. The "non-interference" clause remained in effect for nearly 20 years, transferring hundreds of billions in potential government savings to drug manufacturers.
2021
Aduhelm approved — FDA overrides 10-0 advisory committee vote
Biogen · $56,000/year price · 3 advisory committee members resign in protest
The FDA's own advisory committee votes 10-0 against approving Biogen's Alzheimer's drug Aduhelm. The FDA approves it anyway under its accelerated approval pathway. A subsequent congressional investigation finds that FDA and Biogen had at least 115 documented meetings in the prior 12 months, that the FDA allowed Biogen to help draft the agency's own review documents, and that the FDA had no "clear record" of additional informal meetings. Three advisory committee members resign in protest. Biogen prices the drug at $56,000/year. Aduhelm is eventually discontinued in 2024. See Section 06 for full details.
2022
IRA passes — pharma spends record $384M lobbying, loses the vote
Inflation Reduction Act · first time Medicare can negotiate drug prices
The Inflation Reduction Act passes, allowing Medicare to negotiate prices for the first time in 20 years. The pharmaceutical industry spent $384.5M on lobbying in 2022 — a record — trying to defeat it, and failed. The drug pricing negotiation provision was limited to a small number of drugs and phased in slowly, but it represented the first breach in the non-interference wall that the industry had maintained since 2003. The industry immediately began lobbying to narrow and delay implementation.
Jan 2025
DOGE cuts FDA staff — Neuralink reviewers included in firings
Elon Musk · DOGE · Direct conflict of interest · ~3,500 FDA staff cut
The Department of Government Efficiency, led by Elon Musk, initiates staff reductions at HHS including 3,500 FDA positions. In February 2025, Reuters reports that approximately 20 FDA employees from the office of neurological and physical medicine devices — the unit responsible for reviewing clinical trials for brain-computer interfaces including Neuralink, Musk's own company — were included in the firings. Musk controls both the entity ordering the firings (DOGE) and the company whose regulatory oversight was disrupted. See Section 07 for full details.
section 04 — the revolving door
regulators become lobbyists become regulators
The movement of personnel between the FDA and the pharmaceutical industry is so systematic it has its own name. Former FDA commissioners join pharma boards. Former pharma executives become FDA officials. Former FDA reviewers take jobs at the companies whose drugs they just approved. The result is an agency whose institutional knowledge is partly shaped by the industry it regulates — and an industry whose leadership includes people who understand the agency's internal decision-making better than most of its current staff.
Key finding — OxyContin (1995, DOJ documents)
The two principal FDA reviewers who approved Purdue Pharma's OxyContin new drug application in 1995 both subsequently took positions at Purdue Pharma. One allowed Purdue representatives to help draft his FDA medical officer's review of the drug. Both joined the company they had regulated within years of the approval.
documented post-FDA industry positions — former commissioners and senior officials
| Name |
FDA Role |
Left FDA |
Industry Position |
Compensation (disclosed) |
| Scott Gottlieb |
FDA Commissioner 2017–2019 |
Apr 2019 |
Pfizer Board of Directors (joined Jun 2019); UnitedHealth Board |
~$2.1M from Pfizer board · cash + stock |
| Margaret Hamburg |
FDA Commissioner 2009–2015 |
Mar 2015 |
Alnylam Pharmaceuticals Board |
$2.8M since 2020 |
| Mark McClellan |
FDA Commissioner 2002–2004 |
2004 |
Johnson & Johnson Board of Directors |
$3.3M since 2013 |
| Stephen Ostroff |
Acting FDA Commissioner 2015–2016 |
2016 |
Pfizer consulting |
$752,310 since 2020 |
| OxyContin Reviewer 1 |
Medical Officer, FDA CDER |
~1995–96 |
Purdue Pharma |
Not disclosed |
| OxyContin Reviewer 2 |
Medical Officer, FDA CDER |
~1995–96 |
Purdue Pharma |
Not disclosed |
Key finding — Scott Gottlieb (CNBC, June 2025)
Former FDA Commissioner Scott Gottlieb estimated that as many as 600 drug reviewers have recused themselves from approval processes at any given time because they are currently interviewing with pharmaceutical companies. This means a significant fraction of the FDA's active review workforce may have potential conflicts of interest arising from job-seeking activity — conflicts that are individually disclosed via recusal but that collectively represent a structural problem.
Key finding — 10 of 12 former FDA commissioners (Daily Caller / Dec 2025)
Of twelve former FDA commissioners and acting commissioners who publicly opposed the Trump administration's proposed higher vaccine standards in 2025, ten had disclosed financial ties to pharmaceutical companies — including direct board memberships, consulting arrangements, and speaking fees from vaccine manufacturers. Total documented payments exceeded $6M.
Federal law imposes a one-year "cooling off" period before former senior officials can directly lobby their previous agency. The law does not prohibit board memberships, consulting arrangements, or roles as "advisors" — only registered lobbying contacts. The movement of commissioners to pharma boards occurs within legal boundaries and within months of departure.
section 05 — the accelerated approval pathway
approval without proof
The FDA's Accelerated Approval Program allows drugs for serious conditions to be approved based on a "surrogate endpoint" — a measurable biological marker believed to predict clinical benefit — rather than proven patient outcomes. Companies commit to conduct confirmatory trials after approval. In theory, this gets life-saving drugs to patients faster. In practice, it has become a mechanism by which drugs reach market — and generate billions in revenue — with confirmatory trials that are delayed by years or never completed.
The Scale of the Problem
Of all 278 drug applications granted accelerated approval since 1992, approximately 40% have incomplete confirmatory trials. Thirty-five drugs did not complete at least one required trial by its original planned completion date. Four drugs have confirmatory trials delayed between 5 and nearly 12 years past their original deadlines. Forty-two percent of outstanding confirmatory studies either took more than a year to begin after approval, or had not yet started as of the most recent review.
The Cost to Public Programs
Between 2018 and 2021 alone, Medicare and Medicaid spent more than $18 billion on drugs granted accelerated approval whose confirmatory trials had not been completed by their original planned dates. This represents public program payments for drugs whose long-term clinical benefit had not been demonstrated — in some cases, drugs that were later withdrawn from the market after failing confirmatory trials.
notable accelerated approval cases
| Drug / Company |
Approval Year |
Indication |
Confirmatory Trial Status |
Outcome |
Aduhelm (aducanumab)
Biogen |
Jun 2021 |
Alzheimer's disease |
Not required at approval; FDA overrode adcomm 10-0 vote against |
Discontinued Jan 2024 — Biogen abandoned drug |
Exkivity (mobocertinib)
Takeda |
Sep 2021 |
Lung cancer (EGFR exon 20) |
Confirmatory trial failed primary endpoint |
Withdrawn Oct 2023 |
Zydelig (idelalisib)
Gilead Sciences |
2014 |
Lymphoma |
Failed to complete follow-up studies for 7+ years |
Withdrawn 2022 — 8 years on market without confirmatory data |
Multiple myeloma drug
Not named (FDA action) |
Prior year |
Multiple myeloma |
Confirmatory trials failed to show clinical benefit |
Withdrawn Feb 2023 |
Regeneron applications (2 drugs)
Regeneron Pharmaceuticals |
Applied 2024 |
Undisclosed |
Confirmatory trial not yet started at time of application |
FDA rejected both — rare enforcement of the rules |
The arithmetic: A company can receive accelerated approval, charge full commercial prices to Medicare and Medicaid, collect billions in revenue over years, and then withdraw the drug if the confirmatory trial fails. The upside is entirely private. The downside — including the cost of the failed drug and the opportunity cost of alternative treatments — is borne by patients and public programs.
section 06 — case study: aduhelm
ten votes against. approved anyway.
The FDA's approval of Biogen's Alzheimer's drug Aduhelm in June 2021 represents the clearest documented case of regulatory process failure. The FDA's own advisory committee voted unanimously against approval. The FDA's own statisticians rejected the application. The agency then changed the approval pathway — from traditional to accelerated — without convening a new advisory committee meeting. A congressional investigation found that the approval process violated the FDA's own protocols and involved an unusual degree of collaboration between agency staff and the applicant company.
Primary source — House Oversight Committee / House Energy and Commerce Committee Joint Staff Report (December 2022)
"Documents show that FDA staff and Biogen engaged in at least 115 meetings, calls, and substantive email exchanges over a 12-month period beginning in July 2019 ... the agency confirmed the total number of meetings between agency staff and Biogen during this time is unknown because FDA lacked a 'clear record' of informal meetings ... Documents show that using a joint briefing document afforded Biogen advance insight into FDA's responses and direct guidance from the agency in drafting the company's own sections, including sections drafted by FDA that were then included in Biogen's portion of the document."
Nov 2020
FDA advisory committee votes 10-0 against Aduhelm approval
Three members voted "uncertain" — zero voted in favor
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee convenes to evaluate Biogen's application. The committee finds the clinical trial data insufficient to demonstrate efficacy. The vote: 10 members against, 0 in favor, 1 "uncertain." The FDA is not legally required to follow advisory committee recommendations, but historically it does so in the vast majority of cases. The committee result was unambiguous.
Jun 2021
FDA approves Aduhelm — switches to accelerated approval pathway without new adcomm vote
Price set at $56,000/year · 3 advisory committee members resign
The FDA grants accelerated approval to Aduhelm based on its effect on amyloid plaques in the brain — a surrogate endpoint — rather than demonstrated cognitive benefit. The agency had reviewed the drug under the traditional approval pathway for nine months before pivoting to accelerated approval without reconvening the advisory committee. Three advisory committee members publicly resign in protest, calling the approval "indefensible." Biogen initially prices Aduhelm at $56,000 per year.
2022–2023
Congressional investigation — FDA broke its own protocols
115+ documented FDA-Biogen meetings · unknown additional informal contacts
A joint investigation by the House Oversight Committee and Energy & Commerce Committee produces a 236-page report documenting that FDA staff had extensive, unusually close collaboration with Biogen during the review period. The report finds that FDA staff helped draft portions of Biogen's own submission documents — a reversal of the normal applicant/reviewer relationship. The report concludes that "FDA's atypical collaboration with Biogen" violated the agency's own review protocols and standard independence requirements.
Jan 2024
Biogen discontinues Aduhelm — drug exits market
After $3.3B in planned marketing · Medicare had restricted coverage
Biogen announces it will discontinue Aduhelm and wind down commercialization. The drug's commercial failure was partly attributable to CMS (Medicare) restricting coverage to patients enrolled in clinical trials — a decision made after the controversial approval. Biogen had planned to spend more than $3.3 billion on Aduhelm sales and marketing from 2020 to 2024 — two and a half times what it spent on development. The FDA's accelerated approval granted Biogen years of market access on the basis of an unconfirmed surrogate endpoint. The drug produced no confirmed clinical benefit.
What the record shows: The FDA approved a drug that its own advisory committee unanimously rejected, using a pathway switch that bypassed a second committee review, after 115+ documented meetings with the applicant, with evidence that agency staff helped draft the applicant's own submission. The three committee members who resigned called the approval "indefensible." A congressional report called it a protocol violation. The drug was later discontinued. No FDA official was disciplined.
section 07 — doge dismantles the FDA
the regulator's regulator
Beginning in February 2025, the Department of Government Efficiency — operating with authority delegated from President Trump — began eliminating FDA staff at a scale without precedent in the agency's history. By April 2025, HHS announced 10,000 total agency-wide layoffs, including 3,500 FDA positions. The Center for Drug Evaluation and Research — the division that reviews new drug applications — lost 746 net staff in Q4 FY2025 alone. Among those fired: approximately 20 employees from the division that reviews neurological device clinical trials, including trials for Neuralink, a company owned by the head of DOGE.
The Neuralink conflict — Reuters / Fortune / CNBC reporting (February 2025)
"FDA staff reviewing Musk's Neuralink were included in DOGE employee firings, sources say." — Reuters, February 17, 2025. Approximately 20 employees in the FDA's Office of Neurological and Physical Medicine Devices — responsible for reviewing clinical trial applications for brain-computer interfaces including Neuralink — were terminated. Sources told Reuters they did not believe the Neuralink-assigned reviewers were specifically targeted, but they were included in the wave. Victor Krauthamer, a former FDA official of 30 years: "It's intimidating to the FDA professionals who are overseeing Neuralink's trial. We should be worried about the whole trial and the protection of the people in the trial."
Scale of FDA Staff Reductions
~1,300 FDA probationary workers fired in initial February 2025 wave.
3,500 additional FDA positions eliminated in April 2025 HHS restructuring.
746 net CDER (drug review) staff departed in Q4 FY2025 — the largest single-quarter net loss the center has ever recorded.
194 net CBER (biologics/vaccines) staff departed in Q4 FY2025.
~40% of FDA's Office of Digital Transformation staff eliminated, including the chief information officer and nearly all executive leadership.
Documented Operational Impact
Drug labeling database disrupted: Most drug entries since April 2025 cuts missing labeling information — dosing instructions, approvals, side effects unavailable to prescribers.
First review deadline missed: FDA missed a deadline for a drug for hereditary angioedema due to "heavy workload and limited resources" — first documented DOGE-related review delay.
Pre-IND meeting wait times: Stretched from 3 months to 6 months — posing cash-flow problems for biotech startups with limited runways.
On-time approval rate: Fell from 85-90% historical to 78% in H2 2025.
The structural conflict: Elon Musk is the founder and CEO of Neuralink Corporation, a brain-computer interface company that has received FDA clearance to conduct human clinical trials. Musk simultaneously ran DOGE, which directed the firings of FDA staff, including staff in the division responsible for reviewing Neuralink's clinical trial applications. This is a textbook conflict of interest: the person directing an agency's staffing decisions has a direct financial and commercial interest in the agency's regulatory outcomes.
Cross-investigation
Elon Musk's DOGE also shaped UMAC's drone ban regulatory environment (FCC authority) and directed changes at NHTSA, which regulates Tesla's Autopilot/FSD. Three separate Musk-controlled regulatory intersections — FDA/Neuralink, FCC/drone ban, NHTSA/Tesla — occurred simultaneously under DOGE authority. See the
drone ban investigation → and the
Tesla CEO investigation →
section 08 — the new regime
Kennedy, Makary, and the dismantled advisory system
The 2025 Trump administration installed two controversial figures atop the US health regulatory apparatus: Robert F. Kennedy Jr. as HHS Secretary and Dr. Martin Makary as FDA Commissioner. Kennedy built a career litigating against vaccine manufacturers and receiving contingency fees from anti-vaccine lawsuits — fees his ethics agreement indicates he continues to receive as HHS Secretary. Makary holds active financial interests in multiple companies whose products the FDA regulates. Together, they have reduced the FDA's independent advisory committee process to near-zero while replacing it with handpicked panels operating without public deliberation or conflict-of-interest vetting.
RFK Jr. — HHS Secretary (Confirmed Feb 2025)
Financial conflict: RFK Jr. earned nearly $2.5M in referral fees from Wisner Baum law firm through a 10% contingency arrangement in vaccine injury litigation. His ethics agreement as HHS Secretary indicates these payments continue during his tenure. HHS oversees the National Vaccine Injury Compensation Program — the same program his litigation targets.
Broken promises: CDC pulled $11B in COVID-era vaccination grants from local health departments, despite Kennedy pledging during confirmation hearings not to undermine vaccine funding.
Childhood vaccine schedule reduced (Jan 2026): 17 → 11 routine vaccines. Removed: flu, COVID-19, rotavirus, hepatitis A, hepatitis B, meningococcal.
Marty Makary — FDA Commissioner (Confirmed March 25, 2025, 56–44)
Active industry positions at confirmation:
· Board director at Harrow (ophthalmic pharma): $40K/year
· Advisor, Paragon Health Institute
· Advisor, Sidecar Health (insurance)
· Chief Medical Advisor, Nava (benefits brokerage)
· Chief Medical Officer, Sesame — a telehealth company offering compounded GLP-1 medications. The FDA simultaneously regulates the compounding pharmacy industry that Sesame depends on.
Peter Marks: Director of CBER (the FDA's top vaccine official) resigned March 2025 under pressure, describing policy interference.
collapse of the independent advisory committee system
Key finding — FDA advisory committee meetings, 2025 vs. prior year (BioSpace / CNN reporting)
The FDA held only 7 advisory committee meetings in the period following President Trump's January 2025 inauguration — compared with 22 over the same period the prior year. This represents a 68% decline. FDA is considering ending routine advisory committee reviews of new drugs entirely. Makary has replaced the traditional committee process — in which experts are publicly vetted for conflicts and required to deliberate in public — with ad hoc panels of "handpicked scientists" who support his views, operating without the same transparency requirements.
Key finding — Boston Globe, August 2025
"FDA's new expert panels are rife with financial conflicts and fringe views." Makary's ad hoc panel on estrogen-based drugs "consisted mostly of doctors involved in a pharmaceutical industry campaign opposing FDA warning labels on the drugs." The panels drew criticism from medical experts "for being one-sided" — according to Diana Zuckerman, president of the National Center for Health Research: "It seemed they didn't want any real difference of opinion."
Note on what is and is not documented: This page documents the advisory committee decline, Makary's disclosed financial positions, and RFK Jr.'s documented litigation fees using primary sources and verified reporting. The policy changes documented — vaccine schedule reduction, CDC grant pullback, CBER director departure — are sourced from HHS announcements and contemporaneous reporting. This page does not assert that specific drug approval decisions have been corrupted; it documents the structural conditions under which such corruption becomes possible without detection.
section 09 — the money flow
access for sale
In the months surrounding the 2025 presidential inauguration, pharmaceutical companies donated a record $150 million to Trump's inauguration fund. Individual donations from major drug makers bought documented access: dinner with the Vice President-elect, lunches with Cabinet appointees, meetings with congressional leadership. These donations occurred while the incoming administration was selecting the FDA Commissioner who would oversee the same companies' drug approvals.
documented pharma inauguration donations — January 2025
Pfizer Inc.
4 tickets to "leadership luncheon" with Cabinet appointees + House/Senate leadership
$1.0M
PhRMA
Trade association representing all major drug makers
$1.0M
Bayer
Pharmaceutical + crop science conglomerate
$1.0M
Johnson & Johnson
Pharmaceutical + medical device
$1.0M
Amgen Inc.
2 tickets to "intimate dinner" with VP-elect and Karen Pence
$500K
Total pharma (partial)
Known documented pharma sector — actual total higher
$4.5M+
Context — access for dollars (Fierce Pharma, Rolling Stone reporting)
Pharmaceutical executives paid millions of dollars to "get the ear of the president" in the months following the 2024 election and before the inauguration. Donations were explicitly tiered to access: the $1M tier bought "leadership luncheon" seating with Cabinet appointees and congressional leaders. The $500K tier bought "intimate dinner" access with the Vice President-elect. The FDA Commissioner who would regulate these companies was appointed during this same period.
| Period |
Pharma/Health PAC → Democrats |
Pharma/Health PAC → Republicans |
Total PAC |
Context |
| 2023–2024 cycle |
$5.2M+ |
$6.6M+ |
$11.8M+ |
Pharma hedged bets across both parties |
| 2025 inauguration fund |
— |
$4.5M+ (documented) |
$4.5M+ |
Pfizer, PhRMA, Bayer, J&J, Amgen confirmed |
section 10 — anomalies
what the record shows
Twelve anomalies documented from public records: FEC lobbying disclosures, FDA PDUFA fee schedules, congressional investigation reports, Open Payments database, SEC filings, and verified reporting from primary sources. Click any card to expand.
The FDA's human drug review program depends on $1.42B/year in user fees from pharmaceutical companies — approximately 45% of its total budget for drug reviews. The fee structure is negotiated between the FDA and the pharmaceutical industry, with fees set to fund specific FDA hiring and performance targets. A 2022 JAMA study found that drugs approved closest to their PDUFA deadline (the last month of review) had more post-market safety withdrawals than drugs approved earlier — consistent with deadline pressure affecting review quality. The PDUFA system is legal, disclosed, and renewed by Congress approximately every five years. Its structural conflict is not hidden; it is designed in.
Scott Gottlieb left the FDA in April 2019. He joined Pfizer's board of directors in June 2019 — less than three months later. The one-year cooling-off period for former senior officials applies to registered lobbying contacts, not board memberships. Gottlieb has received approximately $2.1M in cash and stock from his Pfizer board position, where he advises on "ethics and regulatory compliance." He subsequently joined the UnitedHealth board as well. Gottlieb later estimated publicly that 600 active FDA drug reviewers may be recused from cases due to active job negotiations with pharmaceutical companies — a figure that, if accurate, represents an extraordinary fraction of the agency's review capacity.
Documents obtained by the Justice Department during a 2006 review of Purdue Pharma show that the two principal FDA medical officers who reviewed and approved OxyContin in 1995 met with Purdue representatives in a hotel room near FDA offices in January-February 1995 and allowed the company to help draft the FDA's own medical officer review — the core approval document. The label language "believed to reduce abuse liability" was included without clinical evidence. Both FDA reviewers subsequently took positions at Purdue Pharma. OxyContin prescriptions grew from 316,000 in 1996 to 14 million by 2001. More than 500,000 Americans have died from opioid overdoses since 1999.
The Peripheral and Central Nervous System Drugs Advisory Committee voted 10-0 against approving Aduhelm. The FDA's own statisticians rejected the application. The agency then switched from the traditional approval pathway (under which it had reviewed the drug for 9 months) to the accelerated approval pathway — without calling a new advisory committee meeting. A congressional investigation found 115+ documented FDA-Biogen meetings in the prior 12 months, evidence of FDA staff drafting content for Biogen's own submission, and an unknown number of additional informal meetings. Three committee members resigned. The drug was discontinued in 2024. No FDA official was disciplined.
Elon Musk is the founder, CEO, and controlling shareholder of Neuralink Corporation, which received FDA clearance for human clinical trials of a brain-computer interface. Musk simultaneously directed the Department of Government Efficiency, which ordered staffing reductions at federal agencies. In February 2025, approximately 20 employees from the FDA's Office of Neurological and Physical Medicine Devices — the unit reviewing Neuralink's clinical trial applications — were terminated in the DOGE-directed wave. Sources told Reuters they did not believe the Neuralink-assigned staff were specifically targeted. Whether or not they were targeted, the outcome is the same: the man whose company is under active FDA regulatory review directed the personnel decisions of the unit conducting that review.
Robert F. Kennedy Jr. earned approximately $2.5M in referral fees from the law firm Wisner Baum through a 10% contingency fee arrangement in vaccine injury litigation. His ethics agreement as HHS Secretary — which oversees the FDA, CDC, and the National Vaccine Injury Compensation Program — indicates these payments continue during his tenure. At his confirmation hearing, Kennedy appeared to commit to ending this arrangement but later backtracked. HHS oversees the VICP, which is funded by an excise tax on vaccines — the same vaccines that Wisner Baum's litigation targets. The Children's Health Defense organization that Kennedy led has filed approximately 30 federal and state lawsuits since 2020 challenging vaccines and public health mandates.
At the time of his confirmation, Dr. Marty Makary served as Chief Medical Officer at Sesame, a telehealth company that offers patients compounded GLP-1 medications (semaglutide, tirzepatide) — the same drugs at the center of ongoing FDA compounding enforcement actions. The FDA has been adjudicating whether compounded versions of GLP-1 drugs can continue to be sold now that the brand-name drugs (Ozempic, Wegovy, Mounjaro) are off the shortage list. Makary's financial interest in a company that depends on permissive compounding regulation gives him a personal financial stake in FDA decisions his agency was making. This conflict was raised at his confirmation hearing without resolution.
FDA advisory committees provide independent expert review of drug applications, meeting in public with experts vetted for conflicts of interest. Since January 2025, the FDA held only 7 advisory committee meetings — compared with 22 over the same period in prior years, a 68% decline. FDA is considering ending routine advisory committee reviews of new drugs entirely. In their place, Makary has convened "ad hoc expert panels" of handpicked scientists — panels that critics and analysts have described as one-sided, consisting of experts with views aligned with the administration's agenda. Unlike formal advisory committees, these panels operate without standardized conflict-of-interest vetting and without the same public deliberation requirements.
Ten of the twelve former FDA commissioners and acting commissioners who publicly opposed the Trump administration's vaccine policy positions in 2025 disclosed financial ties to pharmaceutical companies, including board memberships, consulting fees, and speaking engagements from vaccine manufacturers. Total documented payments: Margaret Hamburg ($2.8M from Alnylam), Mark McClellan ($3.3M from J&J), Stephen Ostroff ($752K from Pfizer), Scott Gottlieb ($2.1M from Pfizer). The pattern does not establish that these former commissioners' positions were influenced by their financial ties — but it does establish that the institutional voice of "former FDA leadership" is structurally aligned with pharmaceutical industry financial interests.
Of the 278 drug applications granted accelerated approval since 1992, approximately 40% have incomplete confirmatory trials. Thirty-five drugs failed to complete at least one required confirmatory trial by the original planned date. Four drugs have confirmatory trials delayed between 5 and nearly 12 years past their planned completion dates. Between 2018 and 2021, Medicare and Medicaid spent more than $18 billion on drugs with incomplete confirmatory trials. The accelerated approval pathway was designed to speed access to life-saving drugs; the documented record shows it has been used as a mechanism to generate commercial revenue while deferring — sometimes indefinitely — the requirement to prove clinical benefit.
Pharmaceutical companies and their trade association donated at least $4.5M in documented contributions to Trump's January 2025 inauguration fund. Each donation tier purchased explicit access: Pfizer's $1M bought four seats at a "leadership luncheon" with Cabinet appointees and congressional leadership. Amgen's $500K bought two seats at an "intimate dinner" with then-Vice President-elect JD Vance and his wife. The FDA Commissioner who would regulate these companies was appointed in the same period. The donations are legal and disclosed; the access is documented in the inauguration's own materials.
The FDA's Office of Digital Transformation — responsible for protecting the agency's IT systems including systems housing confidential pharmaceutical company trade secrets and proprietary drug application data — had its chief information officer and nearly all of its executive leadership eliminated in DOGE-directed cuts. Approximately 40% of the division's staff departed. FDA tech officials complied with DOGE's requests for data on "critical and essential systems" before the staff reductions; those officials believe the data they provided informed which staff to cut. After the April 2025 layoffs, most drug entries in FDA's publicly accessible labeling database were missing dosing information, approved indications, and safety data — information that prescribers depend on. The FDA's drug data infrastructure was effectively dark for an unknown period.
section 11 — sources
primary sources
This investigation draws on federal lobbying disclosure filings, FDA regulatory records, congressional investigation reports, CMS Open Payments data, SEC proxy statements, and contemporaneous reporting that cites primary documents. All quantitative claims are sourced to the original record.
OpenSecrets / LDA Filings
Pharmaceuticals/Health Products federal lobbying totals 2000–2024. PhRMA annual lobbying spend. Top company spenders. Lobbyist prior-government-employment data.
OpenSecrets.org · Lobbying Disclosure Act database
Federal Register — PDUFA Fee Schedules
FY2024 fee schedule (2023-15911). FY2025 fee schedule. NDA/BLA application fee rates. Annual program fee rates. Total revenue targets.
federalregister.gov · FDA.gov/industry/fda-user-fee-programs
House Oversight / Energy & Commerce — Aduhelm Report
Joint staff report Dec 29, 2022: "The High Price of Aduhelm's Approval." 236 pages documenting FDA-Biogen meetings, joint briefing document, protocol violations.
oversightdemocrats.house.gov · 2022-12-29
Reuters — Neuralink / DOGE firings
Feb 17, 2025: "FDA staff reviewing Musk's Neuralink were included in DOGE employee firings, sources say." ~20 neurological device reviewers included.
reuters.com · reuters.com/technology · Feb 2025
FDA PDUFA Performance Dashboards
FDA-TRACK PDUFA performance data. NDA/BLA Calendar Year Approvals. Novel drug approval counts 2018–2025. Standard vs. priority review timelines.
fda.gov/about-fda/fda-track-agency-wide-program-performance
CMS Open Payments Database
Pharma payments to physicians, researchers, and former officials. Board compensation disclosures cross-referenced with SEC proxy statements.
openpaymentsdata.cms.gov · annual disclosures
Pfizer SEC Proxy Statements
Director compensation disclosures confirming Scott Gottlieb board appointment (Jun 2019), compensation of ~$2.1M cash + stock. Annual proxy filings 2019–2024.
SEC EDGAR · Pfizer CIK 0000078003
HHS / FDA — Staff Reduction Announcements
HHS April 2025 restructuring announcement: 10,000 HHS positions, 3,500 FDA. CDER/CBER staffing data. DOGE-directed reduction-in-force documentation.
hhs.gov · NPR · Axios · STAT News · April 2025
Senate Confirmation Disclosures — Makary / RFK Jr.
Senate HELP Committee ethics questionnaires. Makary board/advisory positions. RFK Jr. litigation fee disclosure. Wisner Baum referral fee arrangement ($2.5M).
help.senate.gov · confirmation hearing transcripts
Inauguration Fund Disclosures
Trump 2025 inaugural fund contributions: Pfizer ($1M), PhRMA ($1M), Bayer ($1M), J&J ($1M), Amgen ($500K). Documented access tiers per donation level.
Fierce Pharma · Rolling Stone · Common Dreams · NYT reporting
GAO / OIG — Accelerated Approval Analysis
278 accelerated approvals analyzed. 40% with incomplete confirmatory trials. $18B Medicare/Medicaid spend on drugs with incomplete trials (2018–2021). 4 drugs 5–12 years delayed.
gao.gov · hhs.gov/oig · FDA accelerated approval program data
DOJ / Congressional Records — OxyContin
2006 DOJ review documents on Purdue Pharma. FDA reviewer hotel meeting with Purdue Jan-Feb 1995. Post-approval employment at Purdue. GAO opioid report. AMA Journal of Ethics (2020).
DOJ records · GAO-04-110 · PMC2622774
Advisory committee data
BioSpace "FDA Went Against Adcomm Votes More, Held Fewer Meetings in 2025." CNN Sept 2025: "Under Trump, FDA seeks to abandon expert reviews of new drugs." Boston Globe Aug 2025: "FDA's new expert panels are rife with financial conflicts."
PDUFA conflict research
"The Prescription Drug User Fee Act: Much More Than User Fees" (PMC8917050). "FDA User Fees: Examining Changes in Medical Product Development" (NBK603243). JAMA 2022 analysis of approval timing and safety outcomes.
Methodology and scope: This investigation documents structural conflicts of interest and anomalies using primary sources — federal lobbying disclosures, FDA fee schedules, congressional investigation reports, and verified contemporaneous reporting. It does not assert that any specific drug approval was made corruptly, nor does it claim that any individual acted with corrupt intent. The pattern of documented conflicts — funding dependence, revolving door, advisory committee collapse — creates conditions in which regulatory independence cannot be independently verified. That is the finding. Source data drawn from LDA filings, FedRegister, FDA.gov, congress.gov, CMS Open Payments, and SEC EDGAR. Data current as of February 2026.